MorphoSys (ETR:MOR) Trading Down 0.6%

MorphoSys AG (ETR:MOR) shares traded down 0.6% during mid-day trading on Monday . The company traded as low as €66.65 ($74.06) and last traded at €66.80 ($74.22). 5,794 shares traded hands during trading, a decline of 96% from the average session volume of 153,687 shares. The stock had previously closed at €67.20 ($74.67).

MorphoSys Stock Down 0.6 %

The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.08, a P/E/G ratio of 0.06 and a beta of 0.66. The business’s 50-day moving average is €67.53 and its two-hundred day moving average is €66.59. The company has a debt-to-equity ratio of 3,454.18, a quick ratio of 3.49 and a current ratio of 1.38.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.